Date	e:2021.9.1		
	r Name: Jia-qi Yuar		
Man	uscript Title:YAP1/MM	P7/CXCL16 axis affects e	fficacy of neoadjuvant chemotherapy via tumor environment
imm	unosuppression in triple-	negative breast cancer	
Man	uscript number (if known	):	
relate part to trelate man The to the med	ted to the content of your ies whose interests may be ansparency and does not tionship/activity/interest, following questions apply suscript only.  author's relationships/activity of hypert ication, even if that medication.	manuscript. "Related" me be affected by the content of necessarily indicate a bias it is preferable that you do to the author's relationsh tivities/interests should be tension, you should declare cation is not mentioned in	ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all su time frame for disclosure	• •	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present	√None	
	manuscript (e.g., funding,		
- 1	provision of study materials,		
	medical writing, article		
-	processing charges, etc.)		
'	No time limit for this item.		
		Time frame: pas	t 36 months
	Grants or contracts from	√None	
	any entity (if not indicated		
	n item #1 above).	/	
F	Royalties or licenses	√None	
	Consulting food	/ Nana	
, [(	Consulting fees	√None	

5	Payment or honoraria for	√None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	
	testimony	
7	Support for attending meetings and/or travel	
8	Patents planned, issued or	
	pending	
9	Participation on a Data	
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	
12	Receipt of equipment,	
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	
	financial interests	
		·
DIa		andlist of interest in the following how

## Please summarize the above conflict of interest in the following box:

All authors certify that they have disclosed all relationships/activities/interests that are related to the content of this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Da	te:2021.9.1		
	ur Name:Ke-jing Zha		
	- — — — — — — — — — — — — — — — — — — —		fficacy of neoadjuvant chemotherapy via tumor environment
	munosuppression in triple-r	<del></del>	
Ma	nuscript number (if known	):	
relator	ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.  Ips/activities/interests as they relate to the current
to me	the epidemiology of hypertedication, even if that medication	ension, you should declare cation is not mentioned in poport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	I planning of the work
	All support for the present	√ None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
	Consulting food	/ None	
r	Consulting fees	√None	

	·		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending		
	meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the f	following box:

All authors certify that they have disclosed all relationships/activities/interests that are related to the content of this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Da	te:2021.9.1		
	ur Name:Shou-man \	<del></del>	
	· —		fficacy of neoadjuvant chemotherapy via tumor environment
	munosuppression in triple-r		
Ma	anuscript number (if known)	):	
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" me e affected by the content of necessarily indicate a bias it is preferable that you do to the author's relationshi ivities/interests should be ension, you should declare cation is not mentioned in	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
CIII	e time mame for disclosure i	s the past 30 months.	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	√None	
	No time limit for this item.		+
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
	III Itelii #1 abovej.		
3	Royalties or licenses	√None	
3	· ·	√None	

	·		
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending		
	meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the f	following box:

All authors certify that they have disclosed all relationships/activities/interests that are related to the content of this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:2021.9.1		
	r Name:Lei Guo		
Mar	nuscript Title:YAP1/MM	P7/CXCL16 axis affects e	efficacy of neoadjuvant chemotherapy via tumor environment
imm	unosuppression in triple-r	negative breast cancer	
Mar	nuscript number (if known)	):	
rela part to ti	ted to the content of your ies whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>
to the control of the	ne epidemiology of hypert lication, even if that medic	ension, you should declard cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	√None	
	No time limit for this item.		
		Time frame: pas	st 36 months
	Grants or contracts from any entity (if not indicated	√None	SC 30 MORENS
	in item #1 above).	_	
. [	Royalties or licenses	√None	

\_None

Consulting fees

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony		
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or pending	√None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
11	Stock or stock options	√None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None	
13	Other financial or non- financial interests	√None	
Ple	ase summarize the above c	onflict of interest in the f	ollowing box:

All authors certify that the of this manuscript.	y have disclosed all relationships/activities/interests that are related to the content

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.